Peter Sever

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. doi request reprint Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm
    Peter S Sever
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, United Kingdom
    J Am Coll Cardiol 62:717-29. 2013
  2. doi request reprint Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
    Peter S Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, 59 North Wharf Road, London W2 1LA, UK
    Eur Heart J 33:2970-9. 2012
  3. pmc Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London, UK
    Eur Heart J 33:486-94. 2012
  4. doi request reprint Coronary heart disease benefits from blood pressure and lipid-lowering
    Peter S Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, London, UK
    Int J Cardiol 135:218-22. 2009
  5. ncbi request reprint Blood pressure reduction is not the only determinant of outcome
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London, W2 1PG, UK
    Circulation 113:2754-72; discussion 2773-4. 2006
  6. ncbi request reprint New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
    Peter Sever
    International Centre for Circulatory Health, Imperial College London, London, UK
    J Renin Angiotensin Aldosterone Syst 7:61-3. 2006
  7. ncbi request reprint Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
    Peter Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, 59 North Wharf Road, London W2 1PG, UK
    Eur Heart J 27:2982-8. 2006
  8. doi request reprint The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London W2 1PG, UK
    Eur Heart J 29:499-508. 2008
  9. pmc Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers
    Gerard F Clunn
    Imperial College London, UK
    Int J Cardiol 139:2-6. 2010
  10. doi request reprint Managing cardiovascular and renal risk: the potential of direct renin inhibition
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, UK
    J Renin Angiotensin Aldosterone Syst 10:65-76. 2009

Detail Information

Publications38

  1. doi request reprint Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm
    Peter S Sever
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, United Kingdom
    J Am Coll Cardiol 62:717-29. 2013
    ..The aim of this study was to determine whether baseline and on-statin C-reactive protein (CRP) are independent predictors of cardiovascular (CV) outcome beyond low-density lipoprotein cholesterol (LDL-C)...
  2. doi request reprint Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
    Peter S Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, 59 North Wharf Road, London W2 1LA, UK
    Eur Heart J 33:2970-9. 2012
    ..In a nested case-control study, we explored the relationship between CV and renal outcomes and all-cause mortality with baseline measurements of PRA among hypertensive adults randomized in the ASCOT trial...
  3. pmc Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London, UK
    Eur Heart J 33:486-94. 2012
    ..We tested whether on-statin C-reactive protein is associated with cardiovascular (CV) outcome in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)...
  4. doi request reprint Coronary heart disease benefits from blood pressure and lipid-lowering
    Peter S Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, London, UK
    Int J Cardiol 135:218-22. 2009
    ..We report further analyses on the combined benefits of these interventions...
  5. ncbi request reprint Blood pressure reduction is not the only determinant of outcome
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London, W2 1PG, UK
    Circulation 113:2754-72; discussion 2773-4. 2006
  6. ncbi request reprint New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
    Peter Sever
    International Centre for Circulatory Health, Imperial College London, London, UK
    J Renin Angiotensin Aldosterone Syst 7:61-3. 2006
    ..Health economic analyses have clearly indicated the cost effectiveness of CCBs which are now elevated to equal standing with diuretics in older patients...
  7. ncbi request reprint Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
    Peter Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, 59 North Wharf Road, London W2 1PG, UK
    Eur Heart J 27:2982-8. 2006
    ....
  8. doi request reprint The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London W2 1PG, UK
    Eur Heart J 29:499-508. 2008
    ..To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA)...
  9. pmc Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers
    Gerard F Clunn
    Imperial College London, UK
    Int J Cardiol 139:2-6. 2010
    ....
  10. doi request reprint Managing cardiovascular and renal risk: the potential of direct renin inhibition
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, UK
    J Renin Angiotensin Aldosterone Syst 10:65-76. 2009
    ..In this article, we review the antihypertensive efficacy of aliskiren and explore its potential in the management of cardiovascular and renal risk...
  11. doi request reprint Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension
    Peter S Sever
    Imperial College London, International Centre for Circulatory Health, London, UK
    J Hypertens 27:947-54. 2009
    ..To determine the cardiovascular benefits of atorvastatin stratified by blood pressure-lowering regimen, 2.2 years after closure of the lipid-lowering arm (LLA) of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA)...
  12. ncbi request reprint ASCOT a four horse race
    Peter Sever
    NHLI Division Imperial College London International Centre for Circulatory Health, London W2 1NY, UK
    J Renin Angiotensin Aldosterone Syst 6:51-4. 2005
  13. ncbi request reprint Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, London, United Kingdom
    Am J Med 118:3-9. 2005
    ....
  14. doi request reprint Hypertension management 2011: optimal combination therapy
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Road, London W2 1LA, UK
    Eur Heart J 32:2499-506. 2011
    ..What then is the next step if blood pressure is not a goal after the patient has been treated with monotherapy for a few weeks? Should you uptitrate, substitute or combine?..
  15. ncbi request reprint Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
    Peter S Sever
    International Center for Circulatory Health, Imperial College London, London, United Kingdom
    Am J Cardiol 96:39F-44F. 2005
    ..These observations support the hypothesis that non-lipid-lowering actions of atorvastatin may have contributed to early protection against CAD in ASCOT-LLA...
  16. doi request reprint The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K
    Peter S Sever
    Clinical Pharmacology and Therapeutics, Imperial College London, International Centre for Circulatory Health, 59 North Wharf Road, London W2 1PG, UK
    Eur Heart J 32:2525-32. 2011
    ..K. population...
  17. ncbi request reprint Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension
    Ben Ariff
    Department of Clinical Pharmacology, International Centre for Circulatory Health, National Heart and Lung Division, Faculty of Medicine, Imperial College, London, England
    Stroke 37:2381-4. 2006
    ..We investigated whether these treatments have different effects on cardiac and large-artery remodelling and evaluated the relation of arterial remodelling to hemodynamic changes in subjects with hypertension...
  18. doi request reprint Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy
    Simon Thom
    International Centre for Circulatory Health, 59 61 North Wharf Rd, Paddington, London W2 1NY, United Kingdom
    Hypertension 54:405-8. 2009
    ..Photographic assessment of the retinal vascular network may be a useful approach to evaluating microvascular structural responses in clinical trials of antihypertensive therapy...
  19. ncbi request reprint Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics
    Ben Ariff
    Department of Clinical Pharmacology Therapeutics, St Marys Hospital, Imperial College, London, UK
    J Renin Angiotensin Aldosterone Syst 3:116-22. 2002
    ..This will lead to a greater understanding of the relationship of these factors to atheroma formation and regression...
  20. doi request reprint Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy
    Anthony J Barron
    Imperial College London, 59 North Wharf Rd, London W2 1LA, United Kingdom
    Hypertension 63:252-8. 2014
    ..This may be a factor contributing to the previously described worse clinical outcome in patients treated with atenolol±bendroflumethiazide compared with amlodipine±perindopril. ..
  21. doi request reprint Wave reflection predicts cardiovascular events in hypertensive individuals independent of blood pressure and other cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudy
    Charlotte Manisty
    International Centre for Circulatory Health, Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom
    J Am Coll Cardiol 56:24-30. 2010
    ....
  22. ncbi request reprint ALLHAT: definitive answers or continuing uncertainty?
    Peter Sever
    Imperial College London, NHLI Division, Department of Clinical Pharmacology, St Mary s Hospital, London, W2 1NY, UK
    J Renin Angiotensin Aldosterone Syst 4:3-5. 2003
  23. doi request reprint Hypotension and ischaemic stroke associated with aliskiren in the ALTITUDE trial: sensitisation of the Bezold-Jarisch reflex?
    Peter Sever
    International Centre for Circulatory Health, Imperial College London, UK
    J Renin Angiotensin Aldosterone Syst 14:1-2. 2013
    ..It is hypothesised that this is best explained by activation of the Bezold-Jarisch reflex, which may be particularly important in circumstances where there is dual blockade of the RAAS...
  24. pmc Blood pressure loci identified with a gene-centric array
    Toby Johnson
    Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
    Am J Hum Genet 89:688-700. 2011
    ....
  25. ncbi request reprint The SCOPE trial. Study on Cognition and Prognosis in the Elderly
    Peter Sever
    NHLI Division, Imperial College of Science, Technology and Medicine, Department of Clinical Pharmacology, St Mary s Hospital, London, UK
    J Renin Angiotensin Aldosterone Syst 3:61-2. 2002
    ..2/1.6 mmHg, thus markedly reducing the overall power of the study. In a number of non-prespecified subgroup analyses, advantages of candesartan over placebo were reported...
  26. doi request reprint Genome-wide analysis of blood pressure variability and ischemic stroke
    Sunaina Yadav
    From the Imperial College Cerebrovascular Research Unit ICCRU S Y, I C, M S K, N H, M P, P E R, P S and International Centre for Circulatory Health P S, Imperial College London, London, United Kingdom Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health E G H, M M, J A, School of Nursing and Midwifery J M M, and School of Biomedical Sciences and Pharmacy R J S, University of Newcastle, Newcastle, New South Wales, Australia Hunter Medical Research Institute, Newcastle, New South Wales, Australia E G H, J M M, M M, R J S, J A Institute for Stroke and Dementia Research ISD, Medical Centre, Klinikum der Universitat Munchen, Ludwig Maximilians University, Munich, Germany R M, M D Munich Cluster for Systems Neurology SyNergy, Munich, Germany R M, M D Stroke and Dementia Research Centre, St George s University of London, London, Germany
    Stroke 44:2703-9. 2013
    ..We sought to determine whether such variability has genetic causes and whether genetic variants associated with BP variability are also associated with ischemic stroke...
  27. doi request reprint The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
    Jan Ostergren
    Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
    J Hypertens 26:2103-11. 2008
    ....
  28. ncbi request reprint Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Peter S Sever
    Imperial College, London, UK
    Lancet 361:1149-58. 2003
    ..No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic...
  29. pmc British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
    Bryan Williams
    Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, Leicester
    BMJ 328:634-40. 2004
  30. ncbi request reprint Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
    Peter Lindgren
    Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
    Eur J Cardiovasc Prev Rehabil 12:29-36. 2005
    ....
  31. ncbi request reprint Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
    Peter S Sever
    Imperial College, London, UK
    Drugs 64:43-60. 2004
    ..No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic...
  32. ncbi request reprint Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
    Peter S Sever
    International Centre for Circulatory Health, NHLI, Faculty of Medicine, Imperial College London, St Mary s Campus, 59 N Wharf Road, London W2 1PG, U K
    Diabetes Care 28:1151-7. 2005
    ..This study aims to establish the benefits of lowering cholesterol in diabetic patients with well-controlled hypertension and average/below-average cholesterol concentrations, but without established coronary disease...
  33. ncbi request reprint Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  34. ncbi request reprint Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
    Neil R Poulter
    Imperial College London, London, UK
    Lancet 366:907-13. 2005
    ..86 and 0.77, respectively). Our aim was to assess to what extent these differences were due to significant differences in blood pressures and in other variables noted after randomisation...
  35. ncbi request reprint Effect of spironolactone on blood pressure in subjects with resistant hypertension
    Neil Chapman
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom
    Hypertension 49:839-45. 2007
    ..Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension...
  36. doi request reprint Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial
    Neil Chapman
    International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London W2 1PG, United Kingdom
    Circulation 118:42-8. 2008
    ..The role of doxazosin in treatment of hypertension remains controversial...
  37. doi request reprint Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication
    Ajay K Gupta
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College, London, UK
    Diabetes Care 31:982-8. 2008
    ..The purpose of this study was to determine the baseline predictors of new-onset diabetes (NOD) in hypertensive patients and to develop a risk score to identify those at high risk of NOD...
  38. doi request reprint Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy
    Andrew Sharp
    International Centre for Circulatory Health, St Mary s Hospital and Imperial College London, London, United Kingdom
    J Am Coll Cardiol 52:1015-21. 2008
    ..We investigated whether diastolic function differs between hypertensive patients of African-Caribbean or white European origin and established whether differences could be explained by confounding variables...